MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
14.42
+0.33
+2.34%
After Hours: 14.46 +0.04 +0.28% 19:55 05/11 EDT
OPEN
14.06
PREV CLOSE
14.09
HIGH
15.55
LOW
13.97
VOLUME
7.24M
TURNOVER
--
52 WEEK HIGH
28.25
52 WEEK LOW
6.83
MARKET CAP
1.74B
P/E (TTM)
-3.7868
1D
5D
1M
3M
1Y
5Y
1D
Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)
TipRanks · 15h ago
Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran
TipRanks · 15h ago
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Intellia Therapeutics (NTLA) and Corvus Pharmaceuticals (CRVS)
TipRanks · 16h ago
Intellia Therapeutics Q1 net loss narrows on lower R&D spending
Reuters · 21h ago
Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimate
Benzinga · 21h ago
Intellia Therapeutics GAAP EPS of -$0.81 beats by $0.08, revenue of $15.04M beats by $1.23M
Seeking Alpha · 21h ago
*Intellia Therapeutics 1Q Research and Development Expenses $80.7M >NTLA
Dow Jones · 21h ago
*Intellia Therapeutics 1Q Rev $15M >NTLA
Dow Jones · 21h ago
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.

Webull offers Intellia Therapeutics Inc stock information, including NASDAQ: NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.